| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | RITA | CTRPv2 | pan-cancer | AAC | 0.093 | 0.008 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | 0.089 | 0.008 |
| mRNA | BRD-K27224038 | CTRPv2 | pan-cancer | AAC | 0.19 | 0.008 |
| mRNA | NSC-207895 | GDSC1000 | pan-cancer | AAC | -0.086 | 0.009 |
| mRNA | QL-XI-92 | GDSC1000 | pan-cancer | AAC | 0.078 | 0.009 |
| mRNA | PF-3758309 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.009 |
| mRNA | CEP-701 | GDSC1000 | pan-cancer | AAC | 0.084 | 0.01 |
| mRNA | PFI-1 | GDSC1000 | pan-cancer | AAC | 0.084 | 0.01 |
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.087 | 0.01 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.13 | 0.01 |